A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Clinical trial NCT06649162 · RECRUITING
Trial details
- NCT number
- NCT06649162
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-09-30
- Primary completion
- 2027-03-01
- Enrollment
- 10000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.